NasdaqCM - Nasdaq Real Time Price USD

Eledon Pharmaceuticals, Inc. (ELDN)

Compare
4.7450
+0.0850
+(1.82%)
At close: 4:00:01 PM EST
4.7450
0.00
(0.00%)
After hours: 4:00:10 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ELDN

Recent News: ELDN

View More
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
GlobeNewswire 15 days ago
Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions

Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) market cap dropped US$48m last week; individual investors who hold 57% were hit as were institutions
Simply Wall St. 2 months ago
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
GlobeNewswire 2 months ago
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
GlobeNewswire 2 months ago
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire 2 months ago
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
GlobeNewswire 2 months ago
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
GlobeNewswire 4 months ago
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
GlobeNewswire 4 months ago
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
GlobeNewswire 5 months ago
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
GlobeNewswire 5 months ago
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
GlobeNewswire 6 months ago
View More

Related Tickers

TSBX Turnstone Biologics Corp.
0.4561
+2.63%
 
ABOS Acumen Pharmaceuticals, Inc.
1.6000
-1.23%
 
RZLT Rezolute, Inc.
4.6000
+1.10%
 
ACRV Acrivon Therapeutics, Inc.
5.55
-0.18%
 
ADAP Adaptimmune Therapeutics plc
0.5900
+1.90%
 
IKNA Ikena Oncology, Inc.
1.4800
-2.63%
 
SABS SAB Biotherapeutics, Inc.
2.0700
-52.52%
 
AVBP ArriVent BioPharma, Inc.
28.80
+1.98%
 
SLNO Soleno Therapeutics, Inc.
48.98
+4.64%
 
OSTX OS Therapies Incorporated
2.6000
+4.00%